Acelyrin, Inc. (SLRN)
NASDAQ: SLRN · Real-Time Price · USD
3.150
-0.070 (-2.17%)
Dec 20, 2024, 4:00 PM EST - Market closed
Acelyrin Employees
Acelyrin had 135 employees as of December 31, 2023. The number of employees increased by 88 or 187.23% compared to the previous year.
Employees
135
Change (1Y)
88
Growth (1Y)
187.23%
Revenue / Employee
n/a
Profits / Employee
-$1,958,556
Market Cap
316.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 135 | 88 | 187.23% |
| Dec 31, 2022 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Viemed Healthcare | 996 |
| Spok Holdings | 384 |
| AirSculpt Technologies | 381 |
| Voyager Therapeutics | 162 |
| Jasper Therapeutics | 45 |
| Immutep | 31 |
| Corvus Pharmaceuticals | 28 |
| Trevi Therapeutics | 25 |
SLRN News
- 11 days ago - ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis - GlobeNewsWire
- 5 weeks ago - Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 6 weeks ago - ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 - GlobeNewsWire
- 3 months ago - Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch - Seeking Alpha
- 3 months ago - ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - GlobeNewsWire
- 4 months ago - ACELYRIN, INC. to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep - Benzinga